心肌做功指数对癌症治疗相关心脏毒性的诊断与预后价值
前瞻性队列纳入136例接受蒽环类和曲妥珠单抗治疗的HER2+乳腺癌女性,系列超声和心脏磁共振评估。GLS绝对变化与同期CTRCD相关,GWI和GCW在GLS变化<3.3%且收缩压下降>21 mmHg时对同期CTRCD有增量诊断价值,但MWIs未改善对后续CTRCD的预测。
要点
- GLS绝对变化与同期及后续CTRCD均独立相关,是核心监测指标。
- GWI和GCW对同期CTRCD诊断有增量价值,尤其GLS变化小且血压下降时。
- MWIs未改善对后续CTRCD的预测,预后评估仍以GLS变化为主。
核心结论
- GLS可用于诊断和预后CMR定义的CTRCD,MWIs在特定病例中提供额外诊断价值。
- GWI和GCW对同期CTRCD诊断有增量价值,但未改善对后续CTRCD的预测。
研究设计与样本
- 前瞻性队列研究,纳入136例接受蒽环类和曲妥珠单抗治疗的HER2+乳腺癌女性。
- 系列超声测量GLS、GWI、GCW、GWW和GWE,以心脏磁共振定义CTRCD。
- 广义估计方程量化GLS和MWIs变化与同期及后续CTRCD的关联,回归树分析探索联合应用。
诊断标准与关键数值
- CTRCD由心脏磁共振定义。
- GLS绝对变化与同期CTRCD相关:sOR 1.97(95%CI 1.07-3.66),P=0.031。
- GWI绝对变化与同期CTRCD相关:sOR 1.73(95%CI 1.04-2.85),P=0.033。
- GLS绝对变化与后续CTRCD相关:sOR 1.79(95%CI 1.22-2.62),P=0.003;GWI sOR 1.67(95%CI 1.20-2.32),P=0.003;GCW sOR 1.65(95%CI 1.17-2.34),P=0.005。
- GLS变化<3.3%(绝对值)且收缩压下降>21 mmHg时,GWI恶化组同期CTRCD概率24.0% vs 5.2%。
临床应用与阅片要点
- 系列监测GLS变化是诊断和预后CTRCD的核心,MWIs可作为补充。
- 当GLS变化较小(<3.3%)且收缩压明显下降(>21 mmHg)时,关注GWI恶化以识别同期CTRCD高风险患者。
- MWIs未显示改善后续CTRCD预测,预后评估仍应基于GLS变化。
局限性
- 单中心前瞻性队列,样本量136例,结论需外部验证。
- 研究人群为HER2+乳腺癌女性接受特定治疗,结果不宜外推至其他癌症或治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Echocardiographic global longitudinal strain (GLS) is a useful measure for detection of cancer treatment-related cardiac dysfunction (CTRCD) but is influenced by blood pressure changes. This limitation may be overcome by assessment of myocardial work (MW), which incorporates blood pressure into the calculation.
OBJECTIVES: This work aims to determine whether myocardial work indices (MWIs) can help diagnose or prognosticate CTRCD.
METHODS: In this prospective cohort study, 136 women undergoing anthracycline and trastuzumab treatment for HER2+ breast cancer, underwent serial echocardiograms and cardiac magnetic resonance pre- and post-anthracycline and every 3 months during trastuzumab. GLS, global work index (GWI), global constructive work (GCW), global wasted work, and global work efficiency were measured. CTRCD was defined with cardiac magnetic resonance. Generalized estimating equations quantified the association between changes in GLS and MWIs and CTRCD at the current (diagnosis) and subsequent visit (prognosis). Regression tree analysis was used to explore the combined use of GLS and MW for the diagnostic/prognostic assessment of CTRCD.
RESULTS: Baseline left ventricular ejection fraction (LVEF) was 63.2 ± 4.0%. Thirty-seven (27.2%) patients developed CTRCD. An absolute change in GLS (standardized odds ratio [sOR]: 1.97 [95% CI: 1.07-3.66]; P = 0.031) and GWI (sOR: 1.73 [95% CI: 1.04-2.85]; P = 0.033) were associated with concurrent CTRCD. An absolute change in GLS (sOR: 1.79 [95% CI: 1.22-2.62]; P = 0.003), GWI (sOR: 1.67 [95% CI: 1.20-2.32]; P = 0.003), and GCW (sOR: 1.65 [95% CI: 1.17-2.34]; P = 0.005) were associated with subsequent CTRCD. Change in GWI and GCW demonstrated incremental value over GLS and clinical factors for the diagnosis of concurrent CTRCD. In a small group with a GLS change <3.3% (absolute), and a >21 mm Hg reduction in systolic blood pressure, worsening of GWI identified patients with higher probability of concurrent CTRCD (24.0% vs 5.2%). MWIs did not improve identification of subsequent CTRCD beyond knowledge of GLS change.
CONCLUSIONS: GLS can be used to diagnose and prognosticate cardiac magnetic resonance (CMR) defined CTRCD, with additional value from MWIs in selected cases. (Evaluation of Myocardial Changes During Breast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI [EMBRACE-MRI]; NCT02306538).
引用
- Calvillo-Argüelles, Thampinathan, Somerset, et al. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity. JACC Cardiovasc Imaging. 2022. PMID: 35926895. doi:10.1016/j.jcmg.2022.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。